Cardiac function in mice lacking the glucagon-like peptide-1 receptor

被引:159
|
作者
Gros, R
You, XM
Baggio, LL
Kabir, MG
Sadi, AM
Mungrue, IN
Parker, TG
Huang, QL
Drucker, DJ
Husain, M
机构
[1] Toronto Gen Hosp, Res Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 2C4, Canada
[3] Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1210/en.2003-0007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide-1 (GLP-1) acts via its G protein-coupled receptor (GLP-1R) to regulate blood glucose. Although the GLP-1R is widely expressed in peripheral tissues, including the heart, and exogenous GLP-1 administration increases heart rate and blood pressure in rodents, the physiological importance of GLP-1R action in the cardiovascular system remains unclear. We now show that 2-month-old mice with genetic deletion of the GLP-1R (GLP-1R(-/-)) exhibit reduced resting heart rate and elevated left ventricular (LV) end diastolic pressure compared with CD-1 wild-type controls. At the age of 5 months, echocardiography and histology demonstrate increased LV thickness in GLP-1R(-/-) mice. Although baseline hemodynamic parameters of GLP-1R(-/-) did not differ significantly from those of wild type, GLP-1R(-/-) mice displayed impaired LV contractility and diastolic function after insulin administration. The defective cardiovascular response to insulin was not attributable to a generalized defect in the stress response, because GLP-1R(-/-) mice responded appropriately to insulin with increased c-fos expression in the hypothalamus and increased circulating levels of glucagon and epinephrine. Furthermore, LV contractility after exogenous epinephrine infusion was also reduced in GLP-1R(-/-) mice. These findings provide new evidence implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo.
引用
收藏
页码:2242 / 2252
页数:11
相关论文
共 50 条
  • [21] Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
    Khan, Sadiya S.
    Ndumele, Chiadi E.
    Kazi, Dhruv S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2025, 333 (02): : 113 - 114
  • [22] Glucagon-Like Peptide-1 Receptor: A Novel Receptor in Platelets
    Kahal, Hassan
    Aburima, Ahmed
    Spurgeon, Benjamin
    Wraith, Katie S.
    Ghavideldarestani, Maryam
    Rizvi, Faran
    Sturmey, Roger G.
    Kilpatrick, Eric S.
    Atkin, Stephen L.
    Naseem, Khalid M.
    DIABETES, 2015, 64 : A528 - A528
  • [23] Impact of glucagon-like peptide-1 on endothelial function
    Sjoholm, A.
    DIABETES OBESITY & METABOLISM, 2009, 11 : 19 - 25
  • [24] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [25] Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders
    Wroge, Jamie
    Williams, Nancy Toedter
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (12) : 1041 - 1050
  • [26] Immunocharacterization and function of glucagon-like peptide-1 islet receptor in syrian hamster
    Boissard, C
    LeclercqMeyer, V
    Pessah, M
    Garel, JM
    Rosselin, G
    Malaisse, WJ
    DIABETOLOGIA, 1997, 40 : 496 - 496
  • [27] Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
    Shchendrygina, Anastasia
    Rakisheva, Amina
    Giverts, Ilya
    Rustamova, Yasmin
    Soloveva, Anzhela
    CARDIAC FAILURE REVIEW, 2024, 10
  • [28] Neuroendocrine function and response to stress mice with complete disruption of glucagon-like peptide-1 receptor signaling
    MacLusky, NJ
    Cook, S
    Scrocchi, L
    Shin, J
    Kim, J
    Vaccarino, F
    Asa, SL
    Drucker, DJ
    ENDOCRINOLOGY, 2000, 141 (02) : 752 - 762
  • [29] Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?
    Iacobellis, Gianluca
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (03): : 224 - 225
  • [30] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37